2012-02-11 03:18:32 - Fast Market Research recommends "Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs" from GBI Research, now available

Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs

Summary

GBI Research, the leading business intelligence provider, has released its latest research "Pricing and Reimbursement in the US - Non-LIS Beneficiaries Not Covered by Medicare Coverage Gap to Gain from Reduction in Out-of-Pocket Expenditure for Generic Drugs". The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in the US with key data, information and analysis of pricing and reimbursement decisions across the US. The report closely scrutinizes major changes in pharmaceuticals-related pricing and reimbursement in the US in the recent past and the impact these changes will have in the

future. It also describes the efforts taken by the US government and private sector in shaping the pricing and reimbursement policies of brand name and generic drugs. The pricing and reimbursement scenario in some of the major therapy areas of the US has been described with the help of informative case studies.


Full Report Details at
- www.fastmr.com/prod/330059_pricing_and_reimbursement_in_the_us_n ..


GBI Research has found that expenditures towards healthcare have increased in the US which has led to an increased life expectancy among the Americans. When compared to the top five countries of Europe (France, Germany, the UK, Italy and Spain), the US has the highest per capita expenditures on healthcare. Out-of-pocket spending is minimal in the US, due to a strong reimbursement system provided by the public and private sector, that covers most age groups and communities. A majority of the US population is under insurance coverage, with private health insurance having a larger share than government health insurance. Most of the states have developed their own insurance plans for the benefit of their residents.

With an increase in the working class and ageing population, chronic diseases, age-related diseases and diseases due to sedentary lifestyle are expected to rise in the future indicating increasing healthcare expenditures. The US President has been implementing a number of changes in the reimbursement system in order to reduce national deficits. The Patient Protection and Affordable Care Act (PPACA) has been introduced to take care of the deficits. The US budget has been designed to reduce deficits and bring about major reforms in the healthcare system of the US.

Scope

* Detailed study of the healthcare systems in the US.
* Political, economical, social and technological analysis of the US pharmaceutical industry.
* Analysis of the pricing and reimbursement mechanisms in the US.
* Key trends that follow from the recent changes brought about in the pricing and reimbursement system.
* Build an understanding of the possible major challenges that may arise due to the changes in the pricing and reimbursement scene in the US.
* Insight into various reimbursement programs in the US with case studies.
* Particular focus on the pricing and reimbursement in major therapy areas with case studies.

Reasons to buy

* Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in the US.
* Optimize your investment through identification and understanding of the changes in the pharmaceuticals regulatory mechanism in the US.
* Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene of the US.
* Improve negotiations with the government agencies to maximize reimbursement of drugs by understanding the mechanisms involved.

Partial Table of Contents:

1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Pricing and Reimbursement in the US - Introduction
2.1 GBI Research Report Guidance
3 Healthcare System in the US - Overview
3.1 Healthcare Expenditure
3.1.1 Healthcare Expenditure and GDP
3.1.2 Healthcare Expenditure by Category
3.2 Healthcare Infrastructure
3.2.1 Hospitals
3.2.2 Hospital Beds
3.2.3 Healthcare Professionals
3.3 Health Insurance
3.3.1 Health Insurance Coverage
3.3.2 Health Insurance Providers
3.4 Demographic Trends Affecting Healthcare
3.4.1 Population Demography
4 Pharmaceutical Regulations in the US - Overview
4.1 Pharmaceutical Industry in the US
4.1.1 PEST Analysis
4.2 Healthcare Regulation
4.2.1 Highlights of the Budget 2011-2012
5 Pricing of Pharmaceutical Drugs in the US
5.1 Pricing Overview
5.1.1 Regulatory Bodies
5.1.2 Pricing Control
5.1.3 340B Drug Pricing Program
5.2 Key Trends
5.2.1 Brand Name Drug Prices Increase in the Face of Generic Competition
5.2.2 Significant Decrease in Average Price of Generic Drugs
5.2.3 PPACA Introduced by the US President to Tackle Soaring Prescription Drug Prices
5.2.4 Generic Price War at Retail Sector
5.3 Major Challenges
5.3.1 Reducing Wastage in Healthcare Spending
5.3.2 Government's Cost Rationalization Efforts will make Future Tough for Big Pharmaceutical Companies
5.3.3 Medicaid Pricing for Dual Eligibles of Medicare Part - D
5.3.4 New ICD-10 (International Classification of Diseases) Coding System
5.3.5 Medicare Part B Drug Pricing Does Not Reflect Market Price Accurately
6 Reimbursement of Pharmaceutical Drugs in the US
6.1 Regulatory Bodies
6.2 Prescription Drugs
6.3 Biologics
6.4 Preferred Drug List (PDL)
6.5 Reimbursement by Health Insurance Companies
6.5.1 UnitedHealth Group
6.5.2 WellPoint, Inc.
6.5.3 Kaiser Foundation Group
6.5.4 Humana Group
6.5.5 Aetna Group
6.6 Pharmacy Benefit Managers (PBMs)
6.7 Reimbursement Programs in the US
6.7.1 Case Studies
6.8 Key Trends
6.8.1 Rebate Reforms and Healthcare Cuts to Reduce Federal Deficit
6.8.2 Medicare Part D Changes in Standard Benefit Parameters
6.8.3 Reimbursement of Brand Name Drugs
6.8.4 Reimbursement of Generic Drugs

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=330059&dt=t

About GBI Research

GBI Research provides industry-leading global business intelligence solutions. Their products and services help companies make better business decisions, win business and position themselves more effectively. GBI Research publishes more than 100 research reports each year across a wide range of industries. These reports draw on in-depth primary and secondary research, databases of proprietary in-house data and high quality analysis from their expert teams. GBI Research employs hundreds of highly qualified Analysts across the US, Europe and Asia. View more research from GBI Research at www.fastmr.com/catalog/publishers.aspx?pubid=1016

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.